Previous Article | Next Article ![]()
Journal of Virology, June 2007, p. 6700-6708, Vol. 81, No. 12
0022-538X/07/$08.00+0 doi:10.1128/JVI.02817-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

Kumar Singh Saikatendu,1,
Vanitha Subramanian,1
Benjamin W. Neuman,2
Michael J. Buchmeier,2
Raymond C. Stevens,3 and
Peter Kuhn1*
Department of Cell Biology,1 Molecular and Integrative Neurosciences Department,2 Department of Molecular Biology, The Scripps Research Institute, 10550 N. Torrey Pines Road, La Jolla, California 920373
Received 20 December 2006/ Accepted 26 March 2007
|
|
|---|
120° into the active site cleft. Furthermore, the catalytic nucleophile Lys 289 points in a diametrically opposite direction, a consequence of an outward displacement of the supporting loop (residues 276 to 295). In the full-length hexameric forms, these two loops are packed against each other and are stabilized by intimate intersubunit interactions. Our results support the hypothesis that absence of an adjacent monomer due to deletion of the hexamerization domain is the most likely cause for disruption of the active site, offering a structural basis for why only the hexameric form of this enzyme is active. |
|
|---|
nsp15 of SARS-CoV is a 346-residue polypeptide that results from the cleavage of pp1ab at sites 6427RLQ
SLE6432 and 6773KLQ
ASQ6778 by the main protease (nsp5). Several recent studies have focused on structural and functional characterization of coronavirus nsp15 due to its potential importance as a drug target. Mutagenic inactivation of this enzyme renders the virus nonviable, as demonstrated with human CoV 229E (14) and equine arteritis virus (EAV; reference 12). nsp15 preferentially cleaves the 3' end of uridylates of RNA at GUU or GU sequences to produce molecules with 2'-3' cyclic phosphate ends (2, 14). It acts on both double-stranded RNA and single-stranded RNA (ssRNA) but with different preferences (2, 14). Mn2+ ions are required for optimal activity (2, 14), with the ion apparently binding weakly to the protein but producing significant conformational changes upon binding (2). The recent structures of full-length nsp15 from SARS-CoV (28) and murine hepatitis virus JHM strain (MHV-JHM) (38) and its eukaryotic homolog, XendoU from Xenopus laevis (27), have provided first structural and mechanistic descriptions of this new enzyme family. Its catalytic center resembles the active site of an unrelated nuclease, RNase A (28).
The biological unit of CoV nsp15 is a hexamer (13) (see Fig. 3a), with its six (potential) active sites distributed along its periphery away from intersubunit interfaces. nsp15 exists in solution in an equilibrium between monomers and hexamers (and sometimes other oligomeric states), but only the hexameric form has been reported to be enzymatically active (13, 38). The link between its hexameric state and its enzymatic activity has not been clear. However, based on our structure of a trimmed monomeric form of SARS-CoV nsp15 (lacking 28 N-terminal and 11 C-terminal residues), we demonstrate evidence for the structural basis underlying this. Examination of the active site strongly suggests that the absence of monomer-monomer interactions within the hexamer destabilizes and significantly displaces two loops (residues 234 to 249 and 276 to 295) in the catalytic domain, resulting in the destruction of the active site in the isolated monomer.
![]() ![]() View larger version (89K): [in a new window] |
FIG. 3. (a) Surface representation of hexameric full-length (FL) nsp15 (PDB code 2H85). The individual subunits are colored and marked A to F. The N-terminal 28 residues of the four monomers A, C, D, and F are shown in red and labeled AN, CN, DN, and FN, respectively. (b) Superposition of truncated (blue) and full-length (yellow) SARS-CoV nsp15 with MHV nsp15 (cyan). The genomic packaging signal of MHV is colored red, and the disordered region is shown as a dotted line. The sequence alignment of the packaging signal of MHV is shown below the ribbon diagram, with the implicated region (P192 - A215) indicated with a red line. Sequence IDs are gi:29837507 for SARS-CoV and gi:37999877 for MHV. (c) Conformational rearrangement of the active site loop and supporting loop in the truncated and full-length forms of nsp15. Truncated monomeric nsp15 is shown in green, while that of the hexameric WT is in light brown. The "supporting loop" (residues 276 to 295) and the "active site loop" (residues 234 to 249) are colored red in monomeric nsp15 and blue in full-length nsp15. Equivalent residues in the active sites of the two structures are labeled (regular font in monomeric nsp15 and in italics for the full-length enzyme). (d) Electron density map (2Fo-Fc) contoured at 1.1 around key residues in the active site of monomeric nsp15.
|
|
|
|---|
Expression and purification. A sequence-verified clone was transformed into Top10 cells (Invitrogen). An overnight culture from a fresh transformant was used to inoculate flasks of 2XYT-ampicillin medium. The culture was grown at 37°C to an optical density at 600 nm of 0.6, induced with 0.2% (wt/vol) L-arabinose, and further grown at 14°C overnight. The cells were harvested by centrifugation and lysed by sonication in buffer containing 50 mM Tris-HCl, pH 8.0, 300 mM NaCl, 10% glycerol, 0.5 mg/ml lysozyme, 100 µl/liter benzonase, and EDTA-free protease inhibitor (one tablet per 50 ml buffer; Roche). The lysate was clarified by ultracentrifugation at 45,000 rpm for 20 min at 4°C, and the soluble fraction was applied onto a metal chelate column (Talon resin charged with cobalt; Clontech). The column was washed with 20 mM Tris-HCl, pH 7.8, 300 mM NaCl, 10% glycerol, 5 mM imidazole and eluted with 25 mM Tris-HCl, pH 7.8, 300 mM NaCl, 150 mM imidazole. The eluate was then fractionated by anion exchange on a Poros HQ column using a linear gradient of NaCl (0 to 1 M) in 25 mM Tris-HCl, pH 8.0. The pure fractions were pooled and concentrated to 1.8 mM. The protein was either flash frozen in liquid nitrogen for later use or used immediately for crystallization trials.
Crystallization and data collection.
Crystals were grown by the nanovolume sitting drop method (30) using drops consisting of 100 nl 1.8 mM protein and 100 nl crystallant. Large (
300-µm by
20-µm by
200-µm) crystals of hexagonal morphology grew typically overnight in 0.2 M sodium bromide, 0.1 M sodium acetate, pH 5.5, and 25% polyethylene glycol (PEG) 2000MME. These were cryoprotected in a solution containing mother liquor and 15% glycerol and flash frozen in liquid nitrogen. While optimizing diffraction, crystals were screened at the Stanford Synchrotron Radiation Laboratory beamlines 1-5, 11-1, 11-3, and 9-1 and the General Medicine and Cancer Institutes Collaborative Access Team (GM/CA-CAT) beamline 23-ID of the Advanced Photon Source (Argonne, IL) by use of Blu-Ice (19). The complete 2.9-Å native data set used for phasing and refinement was collected at the GM/CA-CAT. The reflections were indexed in the primitive hexagonal lattice scaled in P3 using HKL2000 (21). Subsequent molecular replacement attempts (see below) revealed the actual space group to be P31.
Phasing and refinement. Initial phases were obtained by molecular replacement using the full atom monomer structure of full-length SARS-CoV nsp15 (kindly provided by Bruno Canard) with the program Phaser (26) within CCP4 (6) using data from 50.0 to 2.9 Å. Rigid-body refinement using Refmac5 (20) revealed a clearly interpretable electron density map. Phases and the model itself were further improved by one round of Arp/wARP (16). Initial model building was guided by a composite omit map calculated using CNS (4) to minimize model bias. Subsequent improvement of the coordinates was achieved by manual model building in Coot (8) alternating with restrained refinement using Refmac5. Though noncrystallographic symmetry was identified between the four monomers, they were not used during refinement due to subtle differences observed between them in the asymmetric unit. The final model statistics, validation, and stereochemical quality are summarized in Table 1.
|
View this table: [in a new window] |
TABLE 1. Data collection, magnetic resonance, and refinement statistics for nsp15
|
PFO-PAGE. Perfluoro-octanoic acid polyacrylamide gel electrophoresis (PFO-PAGE) was performed according to the method of Ramjeesingh et al. (25) to assess protein stoichiometry. Purified protein samples were mixed 1:1 with PFO loading buffer containing 8% (wt/vol) PFO, 100 mM Tris base, 20% (vol/vol) glycerol, and 0.05% (wt/vol) orange G. Samples were loaded onto precast 4 to 20% Tris-glycine gels, and electrophoresis was performed with a standard Tris-glycine running buffer to which 0.5% (wt/vol) PFO was added. Gels were stained with SYPRO-ruby according to the manufacturer's instructions and photographed with a digital camera attached to a UV light source.
Protein structure accession number. The structure factors and coordinates of the structure have been deposited in the Protein Data Bank (PDB) with accession number 2OZK.
|
|
|---|
![]() View larger version (45K): [in a new window] |
FIG. 1. Electrophoretic mobility shift assays. Monomeric SARS-CoV nsp15 (A and B) and native nsp10 (C and D) were incubated with fluoresceinated ssRNA substrate, and complexes were separated by native electrophoresis on 6% polyacrylamide gels. Fluoresceinated RNA was visualized under UV illumination (A and C), and protein was visualized similarly after SYPRO-ruby poststaining (B and D). Lanes: P, protein only; 0, RNA only; 1 to 7, gradient of protein with a fixed amount of RNA. Free RNA is indicated with a small filled triangle, protein is indicated with a large filled triangle, and protein-RNA complexes are indicated with open triangles. (E) nsp10 was used as a positive control; its binding affinity to the fluoresceinated RNA substrate is shown. The dotted lines indicate the concentration of nsp10 that correlates to 50% binding. (F) PFO-PAGE gel indicating that trimmed nsp15 exists primarily as a monomer and as a dimer; although a variety of larger forms exists, this construct appears to be specifically defective in trimer formation.
|
6 Å). We expressed several C-terminal truncation mutants, deleting from 5 to 19 residues, all of which had comparably high expression levels and were monomeric in solution. Among these, a construct from residues 28 to 335 (described in the rest of this paper) crystallized in a non-PEG condition, which upon optimization with additive screens yielded crystals that diffracted to 2.9 Å. Attempts to improve diffraction using annealing or dehydration (including the procedure described for MHV nsp15 in reference 38) were not successful. It is interesting that while our enzymatically inactive (see below) truncation mutant of nsp15 expressed in high amounts, the full-length wild-type (WT) construct expressed only weakly (data not shown). Ricagno et al. also reported low expression for WT SARS-CoV nsp15 (28). These results taken together reinforces the suggestion by Xu et al. that expression of WT MHV-JHM nsp15 may be toxic to Escherichia coli, causing slow cell growth and low protein yields (38). An incidental mutation, F307L, and active site mutations H262S, H277S, and K317S—all detrimental to enzymatic activity—expressed at much higher levels. Even in EAV NendoU, only the inactive D3014A mutant could be expressed in E. coli, whereas WT expression was not tolerated (22). It is likely that functional nsp15 may act on its own (and also cellular) mRNA, limiting its expression and impeding normal cell growth.
Functional characterization of monomeric nsp15. Bhardwaj et al. reported that only the hexameric form of full-length WT nsp15 binds RNA and that Mn2+ ions increase the affinity of interaction (1). We therefore assessed the ability of monomeric nsp15 construct 28-346 and of seven additional truncation constructs (lacking 5, 7, 9, 11, 13, 15, 17, and 19 C-terminal residues, respectively) to bind and cleave ssRNA. Electrophoretic mobility shift assays did not reveal an interaction between any form of monomeric nsp15 and fluoresceinated ssRNA substrates (Fig. 1), compatible with previous reports (1, 2). These results confirmed that monomeric nsp15 lacks RNA binding activity, as previously reported (1, 2). We do not observe any effect of Mn2+ ions on the affinity of monomeric nsp15 for RNA (data not shown). The modulation of RNA binding by Mn2+ ions is therefore probably a feature only of the intact nsp15 hexamer. XendoU, a structural and functional homologue of viral NendoU from Xenopus laevis, is biologically active as a monomer and does bind RNA in the absence of Mn2+ ions (10). However, changes to the affinity of this interaction in the presence of Mn2+ ions have not been investigated.
Description of the asymmetric unit.
The structure of SARS-CoV nsp15 reported here covers residues 28 to 335 of nsp15 from the Tor2 strain (Fig. 2). Data collection and refinement statistics are summarized in Table 1. Cell content analysis yields a Matthews coefficient of 5.06 and a large solvent content of 74%, which might explain the poor diffraction of these otherwise large (0.3-mm) crystals. The final refined model contains four monomers arranged coaxially in the asymmetric unit of the hexagonal P31 lattice (Fig. 2a). The four monomers exist as two pairs, A/B and C/D. Monomers A and B are virtually identical to each other but differ from monomers C and D (Fig. 2c). The N terminal ß-hairpin is tilted by
45° in monomers A/B in comparison to the pair C/D. None of the intersubunit interactions seen between monomers within the asymmetric unit as well as with their symmetry mates recapitulate those observed for the functionally relevant hexamer of full-length nsp15 of SARS-CoV (Fig. 3a) or MHV.
![]() View larger version (49K): [in a new window] |
FIG. 2. (a) Contents of the asymmetric unit. The four monomers (designated A, B, C, and D) are colored blue, green, cyan, and orange, respectively. (b) The three-domain topology of the truncated SARS-CoV nsp15 monomer. Color is ramped from the N terminus (blue) to the C terminus (red). Secondary structural elements are numbered ß1 to ß13 for ß-strands, while -helices are numbered 1 to 9. (c) Superimposition of the four monomers of the asymmetric unit. Subunits A/B, which form a pair, are colored blue and red, while the other two subunits, C and D, are colored green and magenta, respectively.
|
Structural basis for the functional hexamer.
Most striking of all is the comparison between structures of full-length SARS-CoV nsp15 and our trimmed construct, particularly in the catalytic subunit (Fig. 3c). In monomers A (and B) in the asymmetric unit of our construct, the loop consisting of residues 234 to 249 (referred to here as the "active site loop") spanning the two active site histidines (His 234 and His 249) is flipped by
120° into the active site cleft. Lys 289, another active site residue, points in a diametrically opposite direction (a consequence of a significant displacement of the loop from residues 276 to 295), making it very unlikely to be available for catalysis. Furthermore, it is precisely in each of these regions that significant differences were observed between monomers A/B and C/D in the asymmetric unit of our crystal structure. In C (and D), electron density for these loops is missing, indicating that they are flexibly disordered. In the structures of the functional full-length nsp15 hexamer, the "active site loop" and the "supporting loop" are packed against each other and are stabilized by intimate interactions with residues in the adjacent monomer. Although our structure is of a nominal (2.9-Å) resolution, the electron density for these two loops is quite well ordered in two of the monomers and clearly traceable after residues were deleted in early stages of model improvement as well as in the composite omit map. The electron density around the active site residues is shown in Fig. 3d. Residues Asp239 - Gly246 and Leu248 in the active site loop interact with Ile280, Asp 282, Thr 285 - Lys289, Ser293, and Val294 in the "supporting loop." The supporting loop, in turn, makes extensive interactions with the adjacent monomer (for example monomer A with monomer E in the hexamer; PDB 2H85). Specifically, Lys264, Glu266, Phe268 - Met271, Asn277, Phe279 - Ser288, Cys290, and Gly291 from the supporting loop interact with five sequentially distinct regions on the adjacent monomer (Val9 - His14, Asp16, Thr33, Val35, Val40 - Ile42, Arg61, Ile63, Tyr88, Val162 - Val165, Leu167 - Val172), which form a contiguous patch at the intersubunit interface. In the structure of the truncated form described here, the absence of the adjacent monomer likely causes a peeling away of the "supporting loop" from residues 276 to 295, causing an apparent inward collapse of the "active site loop" from residues 234 to 249 into the active site, thus possibly destroying it. Alternatively, just disorder in this region, as found in chains C and D in our crystal structure, may contribute to a destruction of a productive active site conformation. In chains C and D, the "active site loop" and the "supporting loop" face the large solvent channels in the crystal, while they are stabilized in their "inactive" conformation by crystal contacts in chains A and B.
The eukaryotic structural homologue of NendoU from Xenopus laevis (referred to as XendoU in many studies) exists as a monomer and yet is enzymatically active (10). Structural comparison reveals that the single domain of XendoU corresponds to the catalytic domain of CoV nsp15. Most secondary structure elements of SARS-CoV nsp15 superimpose well with XendoU (Fig. 4). However, there are several additional structural elements in XendoU which decorate the periphery of the molecule, for instance, the helix comprised of residues 10 to 21 followed by a long hairpin loop held together by a short two-stranded ß-sheet (strand 1, residues 32 to 35; strand 2, residues 60 to 62) and a short helical turn (residues 64 to 67). Two helices in the SARS-CoV structure (residues 206 to 213 and 219 to 225) are extended in XendoU (residues 73 to 86 and 96 to 111, respectively). These extensions with a longer connecting loop (10 residues in XendoU compared to 6 residues in SARS-CoV NendoU) act as one of the walls of the monomer, providing stability to the active site, possibly by preventing it from splaying open or collapsing. Two additional helices from residues 113 to 125 and from 133 to 144 provide additional undergirding to the molecule and play a role in stabilizing the active site loop by holding up the loop from residue 165 to 178. Further, residues 145 to 158 form a hairpin loop that also provides stability, holding up the loop consisting of residues 165 to 178. These additional structural elements hold the cup-like molecule together, likely fulfilling the role of adjacent monomers in the CoV nsp15 hexamer. Hence, a comparison of our structure of the monomeric form of nsp15 with those of full-length CoV nsp15 and monomeric XendoU offers a likely structural basis for the catalytic activity of the intact CoV nsp15 hexamer only.
![]() View larger version (53K): [in a new window] |
FIG. 4. Superposition of XendoU structure (PDB ID 2C1W; green) onto the catalytic domain of SARS-CoV NendoU (PDB ID 2H85; light pink). The two disordered loop regions in the XendoU structure are indicated by dotted lines. The secondary structures are numbered using the same scheme as for Fig. 2b. The active site loops of the two structures are highlighted in red.
|
Structural basis for inhibitor design. The activity of nsp15 is critical for the viability of the virus, making it potentially an excellent drug target. As mentioned earlier, mutation of catalytic residues of the NendoUs in human CoV 229E (14) and EAV (22) inactivates the viruses. As described earlier, the monomeric form of nsp15 is inactive due to the loop consisting of residues 234 to 249 falling into the active site. Since this loop fits well into the active site, designed peptide sequences derived from this segment could also be reasonably expected to bind to the active site and could provide a good starting point for the design of inhibitory peptidomimetic molecules, an avenue that is being actively pursued by our group. A second avenue for inhibitor design that is being explored is based on peptides or small molecules that inhibit oligomerization by disruption of the interface. These could be more desirable than active site inhibitors, which could potentially interfere with the similar active sites (such as that of RNase A) in the host cell. They would merely disrupt protein-protein interactions essential for nsp15 hexamerization and hence the activity of the enzyme.
The MHV genomic RNA packaging signal is embedded in the nsp15 ORF. A striking difference between the MHV and SARS-CoV nsp15 structures occurs in the region linking the catalytic and central domains (Fig. 3b). The MHV nsp15 interdomain linker is long and relatively flexible, as evidenced by the lack of observable electron density in the structure, in contrast to the short, structured SARS-CoV linker (28, 38). The MHV genomic RNA packaging signal, which functions at the level of RNA sequence and secondary structure, maps entirely within the extended MHV nsp15 interdomain linker (24). CoVs belonging to group 2a, which includes MHV, are all predicted to encode long nsp15 interdomain linkers with elevated proline and glycine content (25 to 33% P+G), and the genomic RNA packaging signal of bovine CoV maps to this region (7). In contrast, CoVs of groups 1, 2b, and 3 are predicted to contain shorter nsp15 interdomain linkers of the type found in SARS-CoV. Phylogenetic and structural evidence therefore suggests that the nsp15 ORF contains both a likely RNA packaging signal and a likely flexible interdomain protein loop in the group 2a CoVs only.
Several instances of signals that function at the level of RNA structure but are encoded within ORFs are known. Examples for which the structure of the encoded protein is not known include the hepatitis delta virus packaging signal in the large delta antigen ORF (36), the tobacco mosaic virus packaging signal in the GP4 movement protein ORF (35), and the poliovirus cis-acting replication element within the 2C coding region (11). The protein regions encoded by these RNA elements are characterized by elevated proline-plus-glycine (19% P+G) and aspartic acid-plus-glutamic acid (16% D+E) content, consistent with local flexibility at the level of protein structure.
Examples of long RNA signals within ORFs for which the structure of the encoded protein is known include the human rhinovirus cis-acting replication element (reference 18; PDB code 4RHV), black beetle virus and Nodamura virus packaging signals (reference 39; PDB codes 2BBV and 1NOV, respectively), and the MHV packaging signal (reference 37; PDB code 2GTH). These regions are also collectively enriched in proline and glycine (23% P+G) and adopt mainly randomly coiled conformations. As would be expected from the amino acid content, only 16% of the amino acid residues encoded by these RNA elements participate in
-helical and ß-strand secondary structures in the crystallized proteins. Therefore, from the limited data available it would appear that long RNA signals located within protein-encoding regions generally encode randomly coiled, proline- and glycine-rich protein loops.
|
|
|---|
SSRL beamline BL11-1 is supported by the National Institutes of Health (NIH) National Center for Research Resources, NIH National Institutes of General Medical Sciences, Department of Energy, Office of Biological and Environmental Research, Stanford University, and The Scripps Research Institute (TSRI). The GM/CA-CAT beamline (23-ID) is supported by the National Cancer Institute (Y1-CO-1020) and the National Institute of General Medical Sciences (Y1-GM-1104). This study was supported by National Institutes of Allergy and Infectious Disease/NIH contract HHSN 266200400058C, "Functional and Structural Proteomics of the SARS-CoV," to P.K.
This is TSRI manuscript 18649.
Published ahead of print on 4 April 2007. ![]()
J.S.J. and K.S.S. contributed equally to this work. ![]()
|
|
|---|
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»